CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Cytokine release syndrome is a well known complication of CAR-T therapy that can be treated with tocilizumab. This poster presents outcomes for patients treated with locally manufactured antiCD19 CAR-T cells showing that administration of prophylactic tocilizumab prior to infusion on CAR-T cells is associated with reduced incidence of severe CRS and decreased levels of clinical laboratory markers of inflammation and did not appear to impair disease control.